Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 12/20 | 0.46 |
| ▸ | HTR2C | P28335 | 7/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.46 |
| ▸ | DRD2 | P14416 | 3/20 | 0.46 |
| ▸ | HTR4 | Q13639 | 6/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CCR3 | P51677 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3603830 | 0.91 | HTR4 (0.47) | HTR2AKCNH2DRD2HTR4GSK3B | |
| Hydrochloric Acid SCHEMBL3591507 | 0.86 | HTR4 (0.54) | HTR2AHTR2CKCNH2HTR4CCR3 | |
| SCHEMBL3589692 | 0.83 | HTR4 (0.62) | HTR2AKCNH2HTR4GSK3B | |
| Hydrochloric Acid SCHEMBL3595045 | 0.82 | HTR4 (0.61) | HTR2AKCNH2HTR4GSK3B | |
| Hydrochloric Acid SCHEMBL3594885 | 0.80 | HTR2A (0.48) | HTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL3584914 | 0.80 | GSK3B (0.58) | HTR2AKCNH2HTR4GSK3B | |
| SCHEMBL3594752 | 0.80 | KCNH2 (0.54) | HTR2AKCNH2HTR4GSK3B | |
| SCHEMBL3594416 | 0.79 | GSK3B (0.48) | HTR2AKCNH2HTR4GSK3B | |
| Hydrochloric Acid SCHEMBL3589590 | 0.79 | HTR4 (0.63) | HTR2AKCNH2HTR4GSK3B | |
| SCHEMBL3598634 | 0.78 | NPC1 (0.49) | HTR2AKCNH2DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507528-B2 | 2-alkyl-indazole compounds for the treatment of certain cns-related disorders | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2013-08-13 | — | — | US | disclosed |
| EP-2099780-B1 | 2 -ALKYL- INDAZOLE COMPOUNDS FOR THE TREATMENT OF CERTAIN CNS-RELATED DISORDERS | ACRAF (IT) | 2013-01-09 | — | — | EP | disclosed |
| US-20100056573-A1 | 2-ALKYL-INDAZOLE COMPOUNDS FOR THE TREATMENT OF CERTAIN CNS-RELATED DISORDERS | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2010-03-04 | — | — | US | disclosed |
| EP-2099780-A1 | 2 -ALKYL- INDAZOLE COMPOUNDS FOR THE TREATMENT OF CERTAIN CNS-RELATED DISORDERS | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. (IT) | 2009-09-16 | — | — | EP | disclosed |
| WO-2008061688-A1 | 2 -ALKYL- INDAZOLE COMPOUNDS FOR THE TREATMENT OF CERTAIN CNS-RELATED DISORDERS | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056573-A1 | 2-ALKYL-INDAZOLE COMPOUNDS FOR THE TREATMENT OF CERTAIN CNS-RELATED DISORDERS | CYP11B2, CYP1A2, INA | HTR2A 263/4885HTR2C 173/4885KCNH2 393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.